GAITHERSBURG, Md., March 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Wednesday, March 8, 2023 | |||||
Time: | 9:50 – 10:20 a.m. Eastern Standard Time (EST) | |||||
Location: | Boston Marriott Copley Place in Boston, Massachusetts | |||||
Moderator: | Georgi Yordanov, Equity Research Analyst – Biotechnology | |||||
Novavax participant: | John Trizzino, Chief Commercial Officer and Chief Business Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, March 8, 2023 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
CONTACTS
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.93 |
| Daily Change: | 0.22 4.67 |
| Daily Volume: | 4,598,069 |
| Market Cap: | US$689.950M |
April 15, 2024 February 28, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
